TARGETED MODIFIED TNF FAMILY MEMBERS
    4.
    发明公开
    TARGETED MODIFIED TNF FAMILY MEMBERS 有权
    GEZIELTE VERDANDERTE MITGLIEDER DER TNF-FAMILIE

    公开(公告)号:EP3021865A1

    公开(公告)日:2016-05-25

    申请号:EP14741613.5

    申请日:2014-07-18

    IPC分类号: A61K38/19 A61K39/395

    摘要: The present invention relates to a modified cytokine of the TNF superfamily, with reduced activity to its receptor, wherein said modified cytokine is specifically delivered to target cells. Preferably, said modified cytokine is a single chain variant of the TNF superfamily, even more preferably, one or more of the chains carry one or more mutations, resulting in a low affinity to the receptor, wherein said mutant cytokine is specifically delivered to target cells. The targeting is realized by fusion of the modified cytokine of the TNF superfamily to a targeting moiety, preferably an antibody or antibody-like molecule. The invention relates further to the use of such targeted modified cytokine of the TNF superfamily to treat diseases.

    摘要翻译: 本发明涉及TNF受体的活性降低的TNF超家族的修饰细胞因子,其中所述修饰的细胞因子被特异性递送至靶细胞。 优选地,所述修饰的细胞因子是TNF超家族的单链变体,甚至更优选地,一个或多个链携带一个或多个突变,导致对受体的低亲和力,其中所述突变细胞因子被特异性递送至靶细胞 。 靶向通过将TNF超家族的修饰的细胞因子融合到靶向部分,优选抗体或抗体样分子来实现。 本发明进一步涉及TNF超家族的这种靶向修饰的细胞因子的用途来治疗疾病。

    TARGETED MODIFIED IL-1 FAMILY MEMBERS
    8.
    发明公开
    TARGETED MODIFIED IL-1 FAMILY MEMBERS 审中-公开
    ANGEZIELTE MODIFIZIERTE MITGLIEDER DER IL-1-FAMILIE

    公开(公告)号:EP3022226A1

    公开(公告)日:2016-05-25

    申请号:EP14735574.7

    申请日:2014-07-04

    摘要: The present disclosure relates to a modified Interleukin-1 (IL-1) family member cytokine, with reduced activity via its cytokine receptor, wherein said interleukin-1 family member cytokine is specifically delivered to target cells. Preferably, the IL-1 family member cytokine is a mutant, more preferably it is a mutant IL-1 with low affinity to the IL-1 receptor, wherein said mutant IL-1 is specifically delivered to target cells. The targeting is preferably realized by fusion of the modified IL-1 family member cytokine to a targeting moiety, preferably an antibody or antibody-like molecule. The disclosure relates further to the use of such targeted modified IL-1 family member cytokine to treat diseases.

    摘要翻译: 本公开涉及通过其细胞因子受体具有降低的活性的经修饰的白细胞介素-1(IL-1)家族成员细胞因子,其中所述白细胞介素-1家族成员细胞因子被特异性递送至靶细胞。 优选地,IL-1家族成员细胞因子是突变体,更优选是对IL-1受体具有低亲和力的突变IL-1,其中所述突变体IL-1被特异性递送至靶细胞。 靶向优选通过将修饰的IL-1家族成员细胞因子融合到靶向部分,优选抗体或抗体样分子来实现。 本公开进一步涉及这种靶向修饰的IL-1家族成员细胞因子用于治疗疾病的用途。